New Pill DESTROYS Cancer Doctors Called Hopeless

A stethoscope on a dark surface with the word 'CANCER' prominently displayed — CANCER CURE BOMBSHELL

A daily pill doubled pancreatic cancer survival to 13.2 months over chemo in metastatic patients, igniting hope for the deadliest cancer, where 5-year odds hover below 7%.

Story Snapshot

Daraxonrasib monotherapy in second-line PDAC delivered 35% ORR, 92-95% DCR, 8.1-8.5 months PFS, 13.1-15.6 months OS, crushing chemo’s 7.4 months OS benchmark.
Phase I/Ib success triggered three Phase III trials: RASolute 302 recruiting now, readout H1 2026; 303 starts Q4 2025; 304 randomizes first patient Dec 2025.
RAS(ON) multi-selective mechanism targets active RAS mutations in 95% of PDAC cases, long deemed undruggable.
Favorable safety with ≤10% Grade 3+ adverse events positions it for broad use over toxic chemo.
Analysts eye stock surge if Phase III confirms early data, validating Revolution Medicines’ $20B RAS bet.

Phase I/Ib Results Outperform Chemo Benchmarks

Revolution Medicines released Phase I/Ib data from NCT05379985 showing daraxonrasib’s power in advanced PDAC. Second-line metastatic patients with RAS G12X mutations achieved 35% objective response rate and 92% disease control rate.

Median progression-free survival hit 8.5 months, overall survival 13.1 months. These numbers doubled standard gemcitabine/nab-paclitaxel outcomes. First-line monotherapy yielded 47% ORR, combo with chemo 55% ORR. Patients tolerated the drug well, with severe side effects rare.

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/nCo7loNB2R

— CNBC International (@CNBCi) April 13, 2026

Safety data reinforced viability. No more than 10% experienced Grade 3+ treatment-related adverse events. Rash and gastrointestinal issues appeared but stayed manageable. This profile beats chemo’s punishing toxicity, which limits second-line options where PFS lingers at 2-3.5 months.

Revolution calls this a PDAC hat-trick across lines and combos. Small cohorts—26 second-line patients—demand Phase III confirmation, yet early signals scream potential shift.

Pancreatic Cancer’s Brutal Landscape Demands RAS Targeting

PDAC kills fastest among solid tumors, with under 7% five-year survival. RAS mutations drive 95% of cases, especially KRAS G12D and G12V, once undruggable. Standard first-line care relies on gemcitabine/nab-paclitaxel. Second-line options falter, offering 6-7 months overall survival.

Daraxonrasib, a pan-RAS(ON) inhibitor, locks active RAS(ON) states, blocking effector signals in G12X, G13X, Q61X mutants. Revolution built its pipeline around this breakthrough approach for PDAC, lung, colorectal cancers.

Historical chemo failures highlight urgency. No direct RAS inhibitors gained PDAC approval before. Recent precedents like cabozantinib for pancreatic NETs show targeted gains possible.

Seven Phase III PDAC drugs compete now. Daraxonrasib stands out with multi-selectivity over single-mutant focus. Common sense favors tools hitting nearly all cases. Conservative values prize innovation easing patient suffering without endless bureaucracy.

Phase III Trials Accelerate Toward 2026 Readouts

RASolute 302 enrolls 500 second-line RAS-mutated PDAC patients post-chemo, pitting 300mg daraxonrasib against physician-choice chemo. Recruitment finishes end-2025, PFS readout H1 2026.

RASolute 303 tests monotherapy and combo in first-line metastatic PDAC, launching Q4 2025. RASolute 304 targets adjuvant resected PDAC, first randomization December 2025. Revolution confirms trials on track. FDA watches closely given unmet need.

📊 REVOLUTION MEDICINES' POTENTIAL BREAKTHROUGH PANCREATIC CANCER DRUG SUCCEEDS IN LATE-STAGE TRIAL

💡 Revolution Medicines' positive Phase 3 data for daraxonrasib validates RAS inhibition as a viable targeted approach in a cancer type long reliant on toxic chemo, unlocking a…

— Algofinix Inc (@algofinix) April 13, 2026

Analysts set clear bars. Evercore ISI’s Coy Kasimov predicts 5-6 months PFS, 10-11 months OS suffices for success versus chemo’s low hurdle. Oppenheimer and Fidelity anticipate pivotal impacts.

Phase III scales from tiny Phase I groups, risking dilution, yet consistent safety bolsters odds. Confusing prior updates noted, but facts align on efficacy edges. Long-term follow-up from Phase I continues mid-2025 onward.

Analysts Bullish on Market-Shifting Potential

Revolution Medicines holds $20B market cap on RAS promise. Positive RASolute 302 data could spike shares, spur accelerated approval. Long-term, first RAS(ON) nod in PDAC reshapes standards, expanding to front-line and adjuvant.

Patients gain survival doublings, oncologists new tools over chemo. Broader biotech pours into RAS(ON) over OFF inhibitors. Social gains hit hard: families keep loved ones longer.

Expert views converge. Georgetown’s Benjamin Weinberg deems results impressive. Phase I durability awaits full data, but trends hold. Risks linger—side effects, larger trials—but low control arm favors upside.

This aligns American innovation: private enterprise tackles “impossible” via science, not mandates. If Phase III delivers, daraxonrasib redefines PDAC fight.